Skip to main content
Top
Published in: Clinical Rheumatology 12/2019

01-12-2019 | Melanoma | Original Article

Clinical features of patients with anti-melanoma differentiation-associated gene-5 antibody-positive dermatomyositis complicated by spontaneous pneumomediastinum

Authors: Koichi Yamaguchi, Aya Yamaguchi, Miki Itai, Chiharu Kashiwagi, Kazutaka Takehara, Shuhei Aoki, Yuri Sawada, Kohei Taguchi, Kazue Umetsu, Kazuma Oshima, Megumi Uchida, Masao Takemura, Kenichiro Hara, Sei-ichiro Motegi, Yoshinao Muro, Masao Nakasatomi, Toru Sakairi, Keiju Hiromura, Masahiko Kurabayashi, Toshitaka Maeno

Published in: Clinical Rheumatology | Issue 12/2019

Login to get access

Abstract

Background

Dermatomyositis (DM) with autoantibody against melanoma differentiation-associated gene-5 (MDA5) is characterized by elevated risk of rapidly progressive interstitial lung disease (RP-ILD) with a potentially fatal course. Pneumomediastinum (PNM) is a common pulmonary manifestation which accompanies ILD. However, the clinical features of the patients with anti-MDA5 antibody-positive DM who develop PNM remain unclear.

Methods

We retrospectively examined 31 patients with DM having anti-MDA5 antibody and compared the clinical features between patients with PNM (PMN(+)) (n = 11) and those without (PNM(−) (n = 20). In addition, we evaluated the treatment-related prognoses in PNM(+) group.

Results

CT score (total ground-glass opacity (GGO) score, P = 0.02; total fibrosis score, P = 0.02) before treatment, and mortality (P = 0.04) were significantly higher in PNM(+) group. The cumulative survival rate as assessed by Kaplan–Meier method was significantly lower for the PNM(+) group (P = 0.02). Among 11 PMN(+) patients, 9 patients (9/11, 81.8%) underwent intensive immunosuppression therapy for RP-ILD, and 5 patients (5/11, 45.5%) did not respond to it and died from the respiratory failure. At the time of diagnosis of PNM, nonsurvivors had worse liver function (ALT, P = 0.03; LDH, P = 0.01), worse respiratory status (A-aDO2, P = 0.01), and worse CT score (total GGO score, P < 0.01).

Conclusions

A subgroup of patients with DM having anti-MDA5 antibody complicated by PNM as well as RP-ILD did respond to intensive immunosuppression therapy. Initial aggressive immunosuppressive therapy should be considered for these patients.
Key Points
This study clearly demonstrate the presence of PNM was associated with elevated risk of death due to respiratory failure from RP-ILD among patients with DM having circulating anti-MDA5-antibody.
This study demonstrate evaluation of CT image may be helpful to find patients with better response to the intense immunosuppression therapy for the patients with DM having circulating anti-MDA5-antibody and PNM.
Literature
1.
go back to reference Iyer VN, Joshi AY, Ryu JH (2009) Spontaneous pneumomediastinum: analysis of 62 consecutive adult patients. Mayo Clin Proc 84:417–421CrossRef Iyer VN, Joshi AY, Ryu JH (2009) Spontaneous pneumomediastinum: analysis of 62 consecutive adult patients. Mayo Clin Proc 84:417–421CrossRef
2.
go back to reference Sandhya P, Keshava SN, Danda D, Padhan P, Mathew J, Gibikote S (2012) Pneumorrhachis and pneumomediastinum in connective tissue disease-related interstitial lung disease: case series from a tertiary care teaching hospital in South India. Rheumatol Int 32:1415–1419CrossRef Sandhya P, Keshava SN, Danda D, Padhan P, Mathew J, Gibikote S (2012) Pneumorrhachis and pneumomediastinum in connective tissue disease-related interstitial lung disease: case series from a tertiary care teaching hospital in South India. Rheumatol Int 32:1415–1419CrossRef
3.
go back to reference Matsuoka S, Kurihara Y, Yagihashi K, Okamoto K, Niimi H, Nakajima Y (2006) Thin-section CT assessment of spontaneous pneumomediastinum in interstitial lung disease: correlation with serial changes in lung parenchymal abnormalities. Resp Med 100:11–19CrossRef Matsuoka S, Kurihara Y, Yagihashi K, Okamoto K, Niimi H, Nakajima Y (2006) Thin-section CT assessment of spontaneous pneumomediastinum in interstitial lung disease: correlation with serial changes in lung parenchymal abnormalities. Resp Med 100:11–19CrossRef
5.
go back to reference Ma X, Chen Z, Hu W, Guo Z, Wang Y, Kuwana M, Sun L (2016) Clinical and serological features of patients with dermatomyositis complicated by spontaneous pneumomediastinum. Clin Rheumatol 35:489–493CrossRef Ma X, Chen Z, Hu W, Guo Z, Wang Y, Kuwana M, Sun L (2016) Clinical and serological features of patients with dermatomyositis complicated by spontaneous pneumomediastinum. Clin Rheumatol 35:489–493CrossRef
6.
go back to reference Kameda H, Nagasawa H, Ogawa H, Sekiguchi N, Takei H, Tokuhira M, Amano K, Takeuchi T (2005) Combination therapy with corticosteroids, cyclosporin A, and intravenous pulse cyclophosphamide for acute/subacute interstitial pneumonia in patients with dermatomyositis. J Rheumatol 32:1719–1726PubMed Kameda H, Nagasawa H, Ogawa H, Sekiguchi N, Takei H, Tokuhira M, Amano K, Takeuchi T (2005) Combination therapy with corticosteroids, cyclosporin A, and intravenous pulse cyclophosphamide for acute/subacute interstitial pneumonia in patients with dermatomyositis. J Rheumatol 32:1719–1726PubMed
7.
go back to reference Nakashima R, Mimori T (2013) Anti-MDA5 (melanoma differentiation-associated gene 5) antibody and dermatomyositis with rapidly progressive interstitial pneumonia. Nihon Rinsho Men'eki Gakkai kaishi = Japanese J Clin Immunol 36:71–76CrossRef Nakashima R, Mimori T (2013) Anti-MDA5 (melanoma differentiation-associated gene 5) antibody and dermatomyositis with rapidly progressive interstitial pneumonia. Nihon Rinsho Men'eki Gakkai kaishi = Japanese J Clin Immunol 36:71–76CrossRef
8.
go back to reference Sontheimer RD (2002) Dermatomyositis: an overview of recent progress with emphasis on dermatologic aspects. Dermatol Clin 20:387–408CrossRef Sontheimer RD (2002) Dermatomyositis: an overview of recent progress with emphasis on dermatologic aspects. Dermatol Clin 20:387–408CrossRef
9.
go back to reference Moghadam Kia S, Oddis CV, Sato S, Kuwana M, Aggarwal R (2016) Anti-melanoma differentiation-associated gene 5 is associated with rapidly progressive lung disease and poor survival in us patients with amyopathic and myopathic dermatomyositis. Arth Care Res research 68:689–694CrossRef Moghadam Kia S, Oddis CV, Sato S, Kuwana M, Aggarwal R (2016) Anti-melanoma differentiation-associated gene 5 is associated with rapidly progressive lung disease and poor survival in us patients with amyopathic and myopathic dermatomyositis. Arth Care Res research 68:689–694CrossRef
10.
go back to reference Matsushita T, Mizumaki K, Kano M, Yagi N, Tennichi M, Takeuchi A, Okamoto Y, Hamaguchi Y, Murakami A, Hasegawa M (2017) Antimelanoma differentiation-associated protein 5 antibody level is a novel tool for monitoring disease activity in rapidly progressive interstitial lung disease with dermatomyositis. Brit J Dermatol 176:395–402CrossRef Matsushita T, Mizumaki K, Kano M, Yagi N, Tennichi M, Takeuchi A, Okamoto Y, Hamaguchi Y, Murakami A, Hasegawa M (2017) Antimelanoma differentiation-associated protein 5 antibody level is a novel tool for monitoring disease activity in rapidly progressive interstitial lung disease with dermatomyositis. Brit J Dermatol 176:395–402CrossRef
11.
go back to reference Koichi Y, Aya Y, Megumi U, Shunichi K, Masafumi S, Hiroaki M, Masahiko K, Shinsuke K, Manabu U, Kenichiro H (2017) A case of anti-MDA5-positive rapidly progressive interstitial lung disease in a patient with clinically amyopathic dermatomyositis ameliorated by rituximab, in addition to standard immunosuppressive treatment. Mod Rheumatol 27:536–540CrossRef Koichi Y, Aya Y, Megumi U, Shunichi K, Masafumi S, Hiroaki M, Masahiko K, Shinsuke K, Manabu U, Kenichiro H (2017) A case of anti-MDA5-positive rapidly progressive interstitial lung disease in a patient with clinically amyopathic dermatomyositis ameliorated by rituximab, in addition to standard immunosuppressive treatment. Mod Rheumatol 27:536–540CrossRef
12.
go back to reference Yamaguchi K, Yamaguchi A, Kashiwagi C, Sawada Y, Taguchi K, Umetsu K, Oshima K, Uchida M, Suzuki M, Kono S (2018) Differential clinical features of patients with clinically amyopathic dermatomyositis who have circulating anti-MDA5 autoantibodies with or without myositis-associated autoantibodies. Resp Med 140:1–5CrossRef Yamaguchi K, Yamaguchi A, Kashiwagi C, Sawada Y, Taguchi K, Umetsu K, Oshima K, Uchida M, Suzuki M, Kono S (2018) Differential clinical features of patients with clinically amyopathic dermatomyositis who have circulating anti-MDA5 autoantibodies with or without myositis-associated autoantibodies. Resp Med 140:1–5CrossRef
13.
go back to reference Sato S, Murakami A, Kuwajima A, Takehara K, Mimori T, Kawakami A, Mishima M, Suda T, Seishima M, Fujimoto M (2016) Clinical utility of an enzyme-linked immunosorbent assay for detecting anti-melanoma differentiation-associated gene 5 autoantibodies. PLoS One 11:e0154285CrossRef Sato S, Murakami A, Kuwajima A, Takehara K, Mimori T, Kawakami A, Mishima M, Suda T, Seishima M, Fujimoto M (2016) Clinical utility of an enzyme-linked immunosorbent assay for detecting anti-melanoma differentiation-associated gene 5 autoantibodies. PLoS One 11:e0154285CrossRef
14.
go back to reference Muro Y, Sugiura K, Akiyama M (2013) Limitations of a single-point evaluation of anti-MDA5 antibody, ferritin, and IL-18 in predicting the prognosis of interstitial lung disease with anti-MDA5 antibody-positive dermatomyositis. Clin Rheum 32:395–398CrossRef Muro Y, Sugiura K, Akiyama M (2013) Limitations of a single-point evaluation of anti-MDA5 antibody, ferritin, and IL-18 in predicting the prognosis of interstitial lung disease with anti-MDA5 antibody-positive dermatomyositis. Clin Rheum 32:395–398CrossRef
15.
go back to reference Fujiki Y, Kotani T, Isoda K, Ishida T, Shoda T, Yoshida S, Takeuchi T, Makino S (2018) Evaluation of clinical prognostic factors for interstitial pneumonia in anti-MDA5 antibody-positive dermatomyositis patients. Mod Rheumatol 28:133–140CrossRef Fujiki Y, Kotani T, Isoda K, Ishida T, Shoda T, Yoshida S, Takeuchi T, Makino S (2018) Evaluation of clinical prognostic factors for interstitial pneumonia in anti-MDA5 antibody-positive dermatomyositis patients. Mod Rheumatol 28:133–140CrossRef
16.
go back to reference Kazerooni EA, Martinez FJ, Flint A, Jamadar DA, Gross BH, Spizarny DL, Cascade PN, Whyte RI, Lynch J 3rd, Toews G (1997) Thin-section CT obtained at 10-mm increments versus limited three-level thin-section CT for idiopathic pulmonary fibrosis: correlation with pathologic scoring. AJR Am J Roentgenol 169:977–983CrossRef Kazerooni EA, Martinez FJ, Flint A, Jamadar DA, Gross BH, Spizarny DL, Cascade PN, Whyte RI, Lynch J 3rd, Toews G (1997) Thin-section CT obtained at 10-mm increments versus limited three-level thin-section CT for idiopathic pulmonary fibrosis: correlation with pathologic scoring. AJR Am J Roentgenol 169:977–983CrossRef
17.
go back to reference Tang R, Millett CR, Green JJ (2013) Amyopathic dermatomyositis complicated by pneumomediastinum. J Clin Aesth Dermat 6:40 Tang R, Millett CR, Green JJ (2013) Amyopathic dermatomyositis complicated by pneumomediastinum. J Clin Aesth Dermat 6:40
18.
go back to reference Koga T, Fujikawa K, Horai Y, Okada A, S-y K, Iwamoto N, Suzuki T, Nakashima Y, Tamai M, Arima K (2012) The diagnostic utility of anti-melanoma differentiation-associated gene 5 antibody testing for predicting the prognosis of Japanese patients with DM. Rheumatology 51:1278–1284CrossRef Koga T, Fujikawa K, Horai Y, Okada A, S-y K, Iwamoto N, Suzuki T, Nakashima Y, Tamai M, Arima K (2012) The diagnostic utility of anti-melanoma differentiation-associated gene 5 antibody testing for predicting the prognosis of Japanese patients with DM. Rheumatology 51:1278–1284CrossRef
19.
go back to reference Jansen T, Barrera P, Cox N, Laan R (1998) Dermatomyositis with subclinical myositis and spontaneous pneumomediastinum with pneumothorax: case report and review of the literature. Clin Exp Rheumatol 16:733–735PubMed Jansen T, Barrera P, Cox N, Laan R (1998) Dermatomyositis with subclinical myositis and spontaneous pneumomediastinum with pneumothorax: case report and review of the literature. Clin Exp Rheumatol 16:733–735PubMed
20.
go back to reference Cicuttini FM, Fraser K (1989) Recurrent pneumomediastinum in adult dermatomyositis. J Rheumatol 16:384–386PubMed Cicuttini FM, Fraser K (1989) Recurrent pneumomediastinum in adult dermatomyositis. J Rheumatol 16:384–386PubMed
21.
go back to reference Yoshida K, Kurosaka D, Kingetsu I, Hirai K, Yamada A (2008) Pneumomediastinum in dermatomyositis itself is not a poor prognostic factor: report of a case and review of the literature. Rheumatol Int 28:913–917CrossRef Yoshida K, Kurosaka D, Kingetsu I, Hirai K, Yamada A (2008) Pneumomediastinum in dermatomyositis itself is not a poor prognostic factor: report of a case and review of the literature. Rheumatol Int 28:913–917CrossRef
22.
go back to reference Yamanishi HM, Konishi F, Hiyama K, Yamana S, Ishioka S, Yamakido M (1999) Dermatomyositis associated with rapidly progressive fatal interstitial pneumonitis and pneumomediastinum: case report. Scandn J Rheumatol 28:58–61CrossRef Yamanishi HM, Konishi F, Hiyama K, Yamana S, Ishioka S, Yamakido M (1999) Dermatomyositis associated with rapidly progressive fatal interstitial pneumonitis and pneumomediastinum: case report. Scandn J Rheumatol 28:58–61CrossRef
23.
go back to reference Kuroda T, Morikawa H, Satou T, Tanabe Y, Murakami S, Ito S, Nakan M, Gejyo F (2003) A case of dermatomyositis complicated with pneumomediastinum successfully treated with cyclosporin A. Clin Rheumatol 22:45–48CrossRef Kuroda T, Morikawa H, Satou T, Tanabe Y, Murakami S, Ito S, Nakan M, Gejyo F (2003) A case of dermatomyositis complicated with pneumomediastinum successfully treated with cyclosporin A. Clin Rheumatol 22:45–48CrossRef
24.
go back to reference Nonomura Y, Koike R, Nishio J, Tsubata R, Kohsaka H, Kubota T, Miyasaka N (2001) A case of dermatomyositis complicated with pneumomediastinum that was successfully treated with cyclosporin A. Ryumachi[Rheumatism] 41:653–658 Nonomura Y, Koike R, Nishio J, Tsubata R, Kohsaka H, Kubota T, Miyasaka N (2001) A case of dermatomyositis complicated with pneumomediastinum that was successfully treated with cyclosporin A. Ryumachi[Rheumatism] 41:653–658
25.
go back to reference Chan CWS, Chung HY, Lau CS, Tsang HH (2017) Spontaneous pneumomediastinum in a dermatomyositis patient with anti-melanoma differentiation-associated gene-5 antibody and interstitial lung disease despite an initial response to immunosuppressant. Int J Rheum Diseases 22:521–524CrossRef Chan CWS, Chung HY, Lau CS, Tsang HH (2017) Spontaneous pneumomediastinum in a dermatomyositis patient with anti-melanoma differentiation-associated gene-5 antibody and interstitial lung disease despite an initial response to immunosuppressant. Int J Rheum Diseases 22:521–524CrossRef
26.
go back to reference Gürün Kaya A, Çiledağ A, Küçükşahin O, Özdemir Kumbasar Ö, Atasoy Ç (2015) A case of amyopathic dermatomyositis with pneumomediastinum and subcutaneous emphysema. Case Rep Rheumatol 2015:813902PubMedPubMedCentral Gürün Kaya A, Çiledağ A, Küçükşahin O, Özdemir Kumbasar Ö, Atasoy Ç (2015) A case of amyopathic dermatomyositis with pneumomediastinum and subcutaneous emphysema. Case Rep Rheumatol 2015:813902PubMedPubMedCentral
27.
go back to reference Yasuda H, Ikeda T, Hamaguchi Y, Furukawa F (2017) Clinically amyopathic dermatomyositis with rapidly progressive interstitial pneumonia: the relation between the disease activity and the serum interleukin-6 level. J Dermatol 44:1164–1167CrossRef Yasuda H, Ikeda T, Hamaguchi Y, Furukawa F (2017) Clinically amyopathic dermatomyositis with rapidly progressive interstitial pneumonia: the relation between the disease activity and the serum interleukin-6 level. J Dermatol 44:1164–1167CrossRef
Metadata
Title
Clinical features of patients with anti-melanoma differentiation-associated gene-5 antibody-positive dermatomyositis complicated by spontaneous pneumomediastinum
Authors
Koichi Yamaguchi
Aya Yamaguchi
Miki Itai
Chiharu Kashiwagi
Kazutaka Takehara
Shuhei Aoki
Yuri Sawada
Kohei Taguchi
Kazue Umetsu
Kazuma Oshima
Megumi Uchida
Masao Takemura
Kenichiro Hara
Sei-ichiro Motegi
Yoshinao Muro
Masao Nakasatomi
Toru Sakairi
Keiju Hiromura
Masahiko Kurabayashi
Toshitaka Maeno
Publication date
01-12-2019
Publisher
Springer London
Published in
Clinical Rheumatology / Issue 12/2019
Print ISSN: 0770-3198
Electronic ISSN: 1434-9949
DOI
https://doi.org/10.1007/s10067-019-04729-5

Other articles of this Issue 12/2019

Clinical Rheumatology 12/2019 Go to the issue
Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin
Prof. Florian Limbourg
Prof. Anoop Chauhan
Developed by: Springer Medicine
Obesity Clinical Trial Summary

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine